Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892997 | 0.84 | KMT2A (0.46) | ALDH1A1POLBSMN1; SMN2HPGDKMT2A | |
| SCHEMBL4887565 | 0.77 | SLC6A9 (0.43) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL4893181 | 0.77 | THRB (0.43) | ALDH1A1EGFRSMN1; SMN2LMNAKMT2A | |
| SCHEMBL4894897 | 0.76 | KMT2A (0.44) | ALDH1A1SMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL4893717 | 0.76 | L3MBTL1 (0.44) | ALDH1A1SMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL4882730 | 0.76 | THRB (0.42) | ALDH1A1KMT2AMEN1KDM4EGAA | |
| SCHEMBL4896093 | 0.75 | KMT2A (0.46) | ALDH1A1POLBSMN1; SMN2HPGDKMT2A | |
| SCHEMBL4892539 | 0.75 | GAA (0.43) | ALDH1A1SMN1; SMN2LMNAKMT2ATDP1 | |
| SCHEMBL4883922 | 0.75 | RAB9A (0.50) | ALDH1A1SMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL4892456 | 0.70 | THRB (0.38) | ALDH1A1KMT2AMEN1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | ALDH1A1 276/4885EGFR 569/4885POLB 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.